<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have previously reported that <z:chebi fb="11" ids="26333">prostaglandin</z:chebi> A(1) (<z:chebi fb="168" ids="26334,27470">PGA</z:chebi>(1)) reduces <z:mpath ids='MPATH_124'>infarct</z:mpath> size in <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent models</z:e> of focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>This study seeks to elucidate the possible molecular mechanisms underlying <z:chebi fb="168" ids="26334,27470">PGA</z:chebi>(1)'s neuroprotective effects against ischemic injury </plain></SENT>
<SENT sid="2" pm="."><plain>Rats were subjected to permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (pMCAO) by intraluminal suture blockade </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="168" ids="26334,27470">PGA</z:chebi>(1) was injected intracerebroventricularly (icv) immediately after ischemic <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Western blot analysis was employed to determine alterations in IkappaBalpha, pIKKalpha, and peroxisome proliferator-activated receptor-gamma (PPAR-gamma) </plain></SENT>
<SENT sid="5" pm="."><plain>Immunohistochemistry was used to confirm the nuclear translocation of nuclear factor-kappaB (NF-kappaB) p65 and the expression of PPAR-gamma </plain></SENT>
<SENT sid="6" pm="."><plain>RT-PCR was used to detect levels of c-Myc <z:chebi fb="2" ids="33699">mRNA</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>The contribution of PPAR-gamma to <z:chebi fb="168" ids="26334,27470">PGA</z:chebi>(1)'s neuroprotection was evaluated by pretreatment with the PPAR-gamma irreversible <z:chebi fb="68" ids="48706">antagonist</z:chebi> GW9662 </plain></SENT>
<SENT sid="8" pm="."><plain>A brief increase in pIKKalpha levels and rapid reduction in IkappaBalpha were observed after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="168" ids="26334,27470">PGA</z:chebi>(1) blocked <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced increases in pIKKalpha levels and reversed the decline in IkappaBalpha levels </plain></SENT>
<SENT sid="10" pm="."><plain><z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e>-induced nuclear translocation of NF-kappaB p65 was attenuated by <z:chebi fb="168" ids="26334,27470">PGA</z:chebi>(1) </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="168" ids="26334,27470">PGA</z:chebi>(1) also repressed the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced increase in expression of NF-kappaB target gene c-Myc <z:chebi fb="2" ids="33699">mRNA</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>Immunohistochemistry demonstrated an increase in PPAR-gamma immunoreactivity in the nucleus of striatal cells at 3 hr after pMCAO </plain></SENT>
<SENT sid="13" pm="."><plain>Western blot analysis revealed that the expression of PPAR-gamma protein significantly increased at 12 hr and peaked at 24 hr </plain></SENT>
<SENT sid="14" pm="."><plain><z:chebi fb="168" ids="26334,27470">PGA</z:chebi>(1) enhanced the <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-triggered induction of PPAR-gamma protein </plain></SENT>
<SENT sid="15" pm="."><plain>Pretreatment with the irreversible PPAR-gamma <z:chebi fb="68" ids="48706">antagonist</z:chebi> GW9662 attenuated <z:chebi fb="168" ids="26334,27470">PGA</z:chebi>(1)'s neuroprotection against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="16" pm="."><plain>These findings suggest that <z:chebi fb="168" ids="26334,27470">PGA</z:chebi>(1)-mediated neuroprotective effect against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> appears to be associated with blocking NF-kappaB activation and likely with up-regulating PPAR-gamma expression </plain></SENT>
</text></document>